Morepen shareholders approve new unit to house medical device biz

Morepen Laboratories on Wednesday said its shareholders have approved to shift its medical devices business into a newly incorporated wholly-owned subsidiary

medical devices
Representative image
Press Trust of India New Delhi
2 min read Last Updated : Sep 29 2021 | 1:03 PM IST

Morepen Laboratories on Wednesday said its shareholders have approved to shift its medical devices business into a newly incorporated wholly-owned subsidiary.

The new technology focused company -- Morepen Devices Ltd -- will be able to raise capital to fund its growth and make investment on innovation, research, capacity expansion and promotion of its products.

The company shareholders have given their approval for the creation of the new unit on September 28 during the course of the 36th annual general meeting.

The transfer of the business would happen as per terms of the business transfer agreement to be signed between both the companies, Morepen Laboratories said in a statement.

"The Indian POC market is expected to touch USD 16 billion by 2025 and we want to be the No 1 POC player in India with a very large part of our manufacturing being Made in India, Medical Devices Business CEO Anubhav Suri noted.

The global point of care (POC) market is expected to cross USD 51 billion by 2025 and Morepen Devices is rightly placed to grab this opportunity by focusing on backward integration and cost leadership, he added.

The company's POC medical devices business marketed under the brand Dr. Morepen.

Given the scale we are looking to achieve, we will also explore bringing in fresh capital that makes it imperative to have a separate entity to undertake this huge initiative. It will also unlock the value of the medical devices business segment of the company," Morepen Laboratories Chairman and Managing Director Sushil Suri stated.

The proposed segregation will give clarity to the working teams, trade, customers and other stakeholders, the company said.

Morepen produces active pharmaceutical ingredients, formulations and over-the-counter products.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Morepen LaboratoriesMedical device industry

First Published: Sep 29 2021 | 1:03 PM IST

Next Story